08:00 , Dec 7, 2015 |  BC Week In Review  |  Company News

Charles River, Gruenenthal, Nordic Bioscience deal

Argenta Discovery 2009 Ltd. partnered with Gruenenthal and Nordic Bioscience to develop preclinical and clinical assays to optimize the identification of new fibrosis therapies. Argenta will provide preclinical models, primary cell-based assays, in vivo pharmacology...
07:00 , Mar 23, 2015 |  BioCentury  |  Product Development

Galapagos' evolution inflection

Data next month for filgotinib will be the first near-term opportunity for Galapagos N.V. to show it can complete its shift from hybrid discovery/service company into a product-focused play. The Janus kinase-1 (JAK-1) inhibitor will...
07:00 , May 5, 2014 |  BioCentury  |  Finance

Pulling off the AZ gambit

Pfizer Inc. (NYSE:PFE) still has room to maneuver if it is really intent on using its bid for AstraZeneca plc (LSE:AZN; NYSE:AZN) to relocate in the more tax-friendly U.K. The trick is to provide enough...
07:00 , Apr 7, 2014 |  BC Week In Review  |  Company News

Charles River, Galapagos deal

Charles River completed its acquisition of the Argenta Discovery Ltd. and BioFocus DPI Ltd. drug discovery service divisions of Galapagos for €129 million ($177.5 million) in cash, plus up to €5 million ($6.9 million) in...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Company News

Charles River, Galapagos deal

Charles River will acquire the Argenta Discovery Ltd. and BioFocus DPI Ltd. drug discovery service divisions of Galapagos in a deal worth up to €134 million ($186.2 million). Galapagos will receive €129 million ($179.3 million)...
07:00 , Mar 17, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) was off $0.16 to $15.11 last week after submitting an MAA to EMA for Zerenex ferric citrate to treat hyperphosphatemia in dialysis dependent and non-dialysis dependent patients with chronic...
23:39 , Mar 13, 2014 |  BC Extra  |  Company News

Charles River to acquire Galapagos service divisions

CRO Charles River Laboratories International Inc. (NYSE:CRL) will acquire the Argenta Discovery Ltd. and BioFocus drug discovery service divisions of Galapagos N.V. (Euronext:GLPG; Pink:GLPYY) in a deal worth up to EUR 134 million ($186.2 million)....
07:00 , Oct 21, 2013 |  BC Week In Review  |  Company News

Galapagos, Genentech, Roche deal

Galapagos' Argenta Discovery Ltd. drug discovery service division and Roche's Genentech unit extended their 2005 deal for three years to 2016. This is the fourth extension. The companies are collaborating to discover compounds against undisclosed...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Company News

Galapagos management update

Galapagos N.V. (Euronext:GLPG; Pink:GLPYY), Mechelen, Belgium   Business: Autoimmune, Musculoskeletal, Functional genomics   Hired: David Smith as a director and CEO of Galapagos' Argenta Discovery Ltd. and BioFocus service division, a newly created position, formerly...
07:00 , Jul 22, 2013 |  BC Week In Review  |  Company News

Galapagos, Pcovery deal

Galapagos' Argenta Discovery Ltd. drug discovery service company will provide medicinal chemistry, computer-aided drug design services and drug discovery expertise to identify agents against a fungal target for Pcovery. Pcovery said the target is a...